Search
Jefferies London: Protagonist Therapeutics CEO Dinesh Patel responds to takeout speculation and discusses the company's programs and culture of partnering
He covers the company's oral IL-23 (partnered with JNJ), rusfertide (partnered with Takeda), and a new early stage obesity program. Coverage brought to you by
Nov 18
ASCO 2025: Protagonist Therapeutics' CEO Dinesh Patel discusses the results of the phase 3 study of Rusfertide for polycythemia vera, plus a recap of recent ulcerative colitis data for its IL-23R
He describes the Rusfertide result, which is partnered with Takeda and was presented in a plenary session at ASCO. Plus, he covers a UC...
Jun 1
Protagonist Therapeutics' CEO on its hepcidin memetic at #ASH23 and oral IL23 program in I&I
Dinesh Patel describes the science behind Protagonist's polycythemia vera program and oral IL23.
Dec 10, 2023
.png){kind=logo}
